vs
AMREP CORP.（AXR）与TriSalus Life Sciences, Inc.（TLSI）财务数据对比。点击上方公司名可切换其他公司
AMREP CORP.的季度营收约是TriSalus Life Sciences, Inc.的1.1倍（$14.6M vs $13.2M），AMREP CORP.净利率更高（21.6% vs -73.9%，领先95.5%），AMREP CORP.同比增速更快（93.8% vs 59.8%），AMREP CORP.自由现金流更多（$5.4M vs $-2.5M），过去两年TriSalus Life Sciences, Inc.的营收复合增速更高（43.0% vs -13.6%）
AMREP是一家总部位于美国新泽西州普林斯顿的企业，核心业务涵盖房地产与媒体服务领域。公司前身为美国地产石油公司，于1961年正式成立，在相关行业拥有六十余年的发展运营历史。
TriSalus生命科学公司是一家临床阶段生物技术企业，专注于免疫肿瘤学与介入肿瘤学领域，研发专有的靶向给药技术，用于提升肝脏、胰腺等难治性实体瘤患者的治疗效果，主要在北美市场开展临床合作及业务运营。
AXR vs TLSI — 直观对比
营收规模更大
AXR
是对方的1.1倍
$13.2M
营收增速更快
AXR
高出33.9%
59.8%
净利率更高
AXR
高出95.5%
-73.9%
自由现金流更多
AXR
多$7.9M
$-2.5M
两年增速更快
TLSI
近两年复合增速
-13.6%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $14.6M | $13.2M |
| 净利润 | $3.1M | $-9.8M |
| 毛利率 | — | 86.7% |
| 营业利润率 | 20.6% | -24.8% |
| 净利率 | 21.6% | -73.9% |
| 营收同比 | 93.8% | 59.8% |
| 净利润同比 | 338.9% | 3.5% |
| 每股收益（稀释后） | $0.58 | $-0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXRTLSI
| Q1 26 | $14.6M | — | ||
| Q4 25 | $9.4M | $13.2M | ||
| Q3 25 | $17.9M | $11.6M | ||
| Q2 25 | $11.2M | $11.2M | ||
| Q1 25 | $7.5M | $9.2M | ||
| Q4 24 | $11.9M | $8.3M | ||
| Q3 24 | $19.1M | $7.3M | ||
| Q2 24 | $19.5M | $7.4M |
净利润AXRTLSI
| Q1 26 | $3.1M | — | ||
| Q4 25 | $1.2M | $-9.8M | ||
| Q3 25 | $4.7M | $-10.8M | ||
| Q2 25 | $3.9M | $-8.3M | ||
| Q1 25 | $717.0K | $-10.4M | ||
| Q4 24 | $4.0M | $-10.1M | ||
| Q3 24 | $4.1M | $-2.4M | ||
| Q2 24 | $4.1M | $-4.3M |
毛利率AXRTLSI
| Q1 26 | — | — | ||
| Q4 25 | — | 86.7% | ||
| Q3 25 | — | 83.5% | ||
| Q2 25 | — | 83.9% | ||
| Q1 25 | — | 83.7% | ||
| Q4 24 | — | 85.3% | ||
| Q3 24 | — | 86.3% | ||
| Q2 24 | — | 87.6% |
营业利润率AXRTLSI
| Q1 26 | 20.6% | — | ||
| Q4 25 | 11.9% | -24.8% | ||
| Q3 25 | 34.4% | -77.9% | ||
| Q2 25 | 31.7% | -65.4% | ||
| Q1 25 | 5.7% | -79.9% | ||
| Q4 24 | 26.4% | -91.8% | ||
| Q3 24 | 26.1% | -118.9% | ||
| Q2 24 | 23.9% | -111.0% |
净利率AXRTLSI
| Q1 26 | 21.6% | — | ||
| Q4 25 | 12.8% | -73.9% | ||
| Q3 25 | 26.3% | -93.5% | ||
| Q2 25 | 34.8% | -73.9% | ||
| Q1 25 | 9.5% | -113.2% | ||
| Q4 24 | 33.9% | -122.4% | ||
| Q3 24 | 21.3% | -32.6% | ||
| Q2 24 | 21.2% | -58.8% |
每股收益（稀释后）AXRTLSI
| Q1 26 | $0.58 | — | ||
| Q4 25 | $0.22 | $-0.22 | ||
| Q3 25 | $0.87 | $-0.96 | ||
| Q2 25 | $0.73 | $-0.27 | ||
| Q1 25 | $0.13 | $-0.39 | ||
| Q4 24 | $0.75 | $-0.38 | ||
| Q3 24 | $0.76 | $-0.12 | ||
| Q2 24 | $0.77 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $50.0M | $20.4M |
| 总债务越低越好 | $21.0K | — |
| 股东权益账面价值 | $139.4M | $-33.9M |
| 总资产 | $143.9M | $35.3M |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资AXRTLSI
| Q1 26 | $50.0M | — | ||
| Q4 25 | $44.6M | $20.4M | ||
| Q3 25 | $48.9M | $22.7M | ||
| Q2 25 | $39.5M | $26.5M | ||
| Q1 25 | $36.9M | $13.0M | ||
| Q4 24 | $40.1M | $8.5M | ||
| Q3 24 | $40.4M | $11.3M | ||
| Q2 24 | $29.7M | $16.5M |
总债务AXRTLSI
| Q1 26 | $21.0K | — | ||
| Q4 25 | $23.0K | — | ||
| Q3 25 | $25.0K | — | ||
| Q2 25 | $26.0K | — | ||
| Q1 25 | $29.0K | — | ||
| Q4 24 | $32.0K | — | ||
| Q3 24 | $34.0K | — | ||
| Q2 24 | $35.0K | — |
股东权益AXRTLSI
| Q1 26 | $139.4M | — | ||
| Q4 25 | $136.0M | $-33.9M | ||
| Q3 25 | $134.7M | $-26.7M | ||
| Q2 25 | $130.0M | $-19.4M | ||
| Q1 25 | $126.0M | $-34.4M | ||
| Q4 24 | $125.1M | $-25.9M | ||
| Q3 24 | $122.2M | $-20.4M | ||
| Q2 24 | $118.0M | $-25.3M |
总资产AXRTLSI
| Q1 26 | $143.9M | — | ||
| Q4 25 | $140.1M | $35.3M | ||
| Q3 25 | $140.7M | $36.5M | ||
| Q2 25 | $133.8M | $41.3M | ||
| Q1 25 | $128.9M | $28.6M | ||
| Q4 24 | $129.1M | $24.0M | ||
| Q3 24 | $127.0M | $27.5M | ||
| Q2 24 | $122.8M | $32.4M |
负债/权益比AXRTLSI
| Q1 26 | 0.00× | — | ||
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.4M | $-2.5M |
| 自由现金流经营现金流 - 资本支出 | $5.4M | $-2.5M |
| 自由现金流率自由现金流/营收 | 37.0% | -19.1% |
| 资本支出强度资本支出/营收 | 0.1% | 0.3% |
| 现金转化率经营现金流/净利润 | 1.72× | — |
| 过去12个月自由现金流最近4个季度 | $20.2M | $-19.1M |
8季度趋势，按日历期对齐
经营现金流AXRTLSI
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-4.3M | $-2.5M | ||
| Q3 25 | $9.5M | $-3.7M | ||
| Q2 25 | $10.2M | $-7.3M | ||
| Q1 25 | $-3.2M | $-4.5M | ||
| Q4 24 | $-182.0K | $-5.7M | ||
| Q3 24 | $10.7M | $-10.8M | ||
| Q2 24 | $10.7M | $-13.4M |
自由现金流AXRTLSI
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-4.3M | $-2.5M | ||
| Q3 25 | $9.5M | $-3.9M | ||
| Q2 25 | $9.7M | $-7.4M | ||
| Q1 25 | $-3.3M | $-5.3M | ||
| Q4 24 | $-268.0K | $-5.8M | ||
| Q3 24 | $10.7M | $-11.0M | ||
| Q2 24 | $10.3M | $-13.5M |
自由现金流率AXRTLSI
| Q1 26 | 37.0% | — | ||
| Q4 25 | -45.9% | -19.1% | ||
| Q3 25 | 53.2% | -33.9% | ||
| Q2 25 | 86.4% | -66.1% | ||
| Q1 25 | -43.4% | -57.3% | ||
| Q4 24 | -2.3% | -69.7% | ||
| Q3 24 | 55.8% | -149.9% | ||
| Q2 24 | 52.5% | -183.1% |
资本支出强度AXRTLSI
| Q1 26 | 0.1% | — | ||
| Q4 25 | 0.6% | 0.3% | ||
| Q3 25 | 0.1% | 1.9% | ||
| Q2 25 | 5.2% | 0.8% | ||
| Q1 25 | 0.3% | 8.2% | ||
| Q4 24 | 0.7% | 0.6% | ||
| Q3 24 | 0.2% | 2.3% | ||
| Q2 24 | 2.3% | 0.8% |
现金转化率AXRTLSI
| Q1 26 | 1.72× | — | ||
| Q4 25 | -3.54× | — | ||
| Q3 25 | 2.03× | — | ||
| Q2 25 | 2.63× | — | ||
| Q1 25 | -4.51× | — | ||
| Q4 24 | -0.05× | — | ||
| Q3 24 | 2.63× | — | ||
| Q2 24 | 2.59× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
